Christian Lemaire

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9379798/publications.pdf

Version: 2024-02-01

	840776	839539
515	11	18
citations	h-index	g-index
19	19	635
docs citations	times ranked	citing authors
	citations 19	515 11 h-index 19 19

#	Article	IF	CITATIONS
1	The pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain. EJNMMI Research, 2021, 11, 36.	2.5	5
2	Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy. Molecular Imaging and Biology, 2020, 22, 1197-1207.	2.6	13
3	Radical C–H 18F-Difluoromethylation of Heteroarenes with [18F]Difluoromethyl Heteroaryl-Sulfones by Visible Light Photoredox Catalysis. Catalysts, 2020, 10, 275.	3.5	9
4	Development of a General Automated Flow Photoredox ¹⁸ F-Difluoromethylation of N-Heteroaromatics in an AllinOne Synthesizer. Organic Process Research and Development, 2020, 24, 734-744.	2.7	23
5	Lateâ€Stage ¹⁸ Fâ€Difluoromethyl Labeling of Nâ€Heteroaromatics with High Molar Activity for PET Imaging. Angewandte Chemie - International Edition, 2019, 58, 13149-13154.	13.8	51
6	Evaluating the In Vivo Specificity of [18F]UCB-H for the SV2A Protein, Compared with SV2B and SV2C in Rats Using microPET. Molecules, 2019, 24, 1705.	3.8	9
7	Progress in Difluoroalkylation of Organic Substrates by Visible Light Photoredox Catalysis. Advanced Synthesis and Catalysis, 2019, 361, 1500-1537.	4.3	143
8	Fully Automated Synthesis and Evaluation of [¹⁸ F]BPAM121: Potential of an AMPA Receptor Positive Allosteric Modulator as PET Radiotracer. ChemMedChem, 2019, 14, 788-795.	3.2	4
9	Quantification of [18F]UCB-H Binding in the Rat Brain: From Kinetic Modelling to Standardised Uptake Value. Molecular Imaging and Biology, 2019, 21, 888-897.	2.6	10
10	Progress in Lanthionine and Protected Lanthionine Synthesis. Chemistry - A European Journal, 2018, 24, 15421-15441.	3.3	16
11	Frontispiece: Progress in Lanthionine and Protected Lanthionine Synthesis. Chemistry - A European Journal, 2018, 24, .	3.3	O
12	Pharmacokinetic Characterization of [$<$ sup $>$ 18 $<$ /sup $>$ F]UCB-H PET Radiopharmaceutical in the Rat Brain. Molecular Pharmaceutics, 2017, 14, 2719-2725.	4.6	29
13	Enabling Efficient Positron Emission Tomography (PET) Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) with a Robust and One-Step Radiosynthesis of a Highly Potent ¹⁸ F-Labeled Ligand ([¹⁸ F]UCB-H). Journal of Medicinal Chemistry, 2016, 59, 8955-8966.	6.4	47
14	Fully automated radiosynthesis of N1-[18F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging. Nuclear Medicine and Biology, 2016, 43, 379-389.	0.6	28
15	Enantioselective synthesis of α-benzylated lanthionines and related tripeptides for biological incorporation into E. coli peptidoglycan. Organic and Biomolecular Chemistry, 2014, 12, 9853-9863.	2.8	7
16	Evaluation of ¹⁸ F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain. Journal of Nuclear Medicine, 2014, 55, 1336-1341.	5.0	65
17	Stereoselective synthesis of lanthionine derivatives in aqueous solution and their incorporation into the peptidoglycan of Escherichia coli. Bioorganic and Medicinal Chemistry, 2014, 22, 4621-4628.	3.0	16
18	Synthesis of protected α-alkyl lanthionine derivatives. Tetrahedron, 2014, 70, 4526-4533.	1.9	8

#	Article	IF	CITATIONS
19	Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Research, 2013, 3, 35.	2.5	32